object
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
caus
fatal
infect
patient
middl
east
travelerassoci
secondari
case
europ
africa
persontoperson
transmiss
evid
outbreak
involv
household
hospit
contact
effect
antivir
urgent
need
method
use
small
compoundbas
forward
chemic
genet
screen
chemic
librari
known
drug
influenza
viru
biosafeti
laboratori
assess
antimerscov
activ
identifi
compound
interferon
nelfinavir
lopinavir
report
anticoronaviru
activ
term
cytopath
effect
inhibit
viral
yield
reduct
plaqu
reduct
assay
biosafeti
laboratori
result
ten
compound
identifi
primari
hit
highthroughput
screen
mycophenol
acid
exhibit
low
ec
high
select
index
addit
ribavirin
interferon
also
exhibit
invitro
antimerscov
activ
serum
concentr
achiev
therapeut
dose
mycophenol
acid
time
higher
concentr
invitro
antimerscov
activ
demonstr
wherea
journal
infect
ribavirin
time
lower
combin
mycophenol
acid
lower
ec
drug
time
conclus
mycophenol
acid
consid
treatment
trial
mer
novel
lineag
c
betacoronaviru
previous
known
human
coronaviru
later
renam
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
arabian
peninsula
sinc
april
caus
sever
acut
respiratori
syndrom
sar
like
diseas
laboratoryconfirm
case
fatal
countri
middl
east
europ
north
africa
octob
animaltohuman
transmiss
suspect
view
merscov
close
phylogenet
related
lineag
c
betacoronavirus
found
bat
hong
kong
mexico
europ
africa
broad
speci
tropism
variou
anim
cell
line
includ
bat
primat
pig
civet
rabbit
recent
serolog
studi
major
livestock
suggest
dromedari
camel
possibl
host
base
high
preval
merscov
neutral
antibodi
dromedari
camel
oman
howev
target
studi
need
confirm
find
possibl
relev
human
case
merscov
infect
case
contact
camel
viru
isol
anim
yet
epidem
continu
evolv
recent
outbreak
occur
among
epidemiologicallylink
household
contact
kingdom
saudi
arabia
unit
kingdom
itali
tunisia
hospit
contact
kingdom
saudi
arabia
jordan
unit
kingdom
franc
provid
evid
merscov
potenti
persontoperson
transmiss
unlik
human
coronaviru
infect
gener
mild
patient
mer
suffer
rapidli
progress
pneumonia
also
develop
acut
renal
failur
hepat
dysfunct
gastrointestin
upset
pericard
dissemin
intravascular
coagul
andor
cytopenia
result
crude
mortal
rate
nearli
document
case
far
exceed
seen
human
coronaviru
infect
includ
sar
despit
aggress
support
treatment
includ
extracorpor
membran
oxygen
mer
case
mild
asymptomat
case
recogn
recent
case
cluster
signifi
global
health
threat
especi
view
unusu
clinic
sever
mer
travel
infect
person
countri
influx
religi
pilgrim
kingdom
saudi
arabia
lack
proven
effect
specif
antivir
treatment
initi
success
appli
chemic
genet
probe
novel
target
compound
antivir
develop
start
look
broadspectrum
antivir
compound
may
activ
influenza
virus
coronavirus
two
viral
pathogen
respons
caus
recent
pandem
largescal
epidem
neuraminidas
inhibitor
oseltamivir
zanamivir
remain
effect
season
avian
influenza
virus
proven
antivir
therapeut
option
coronaviru
infect
lack
given
limit
time
avail
develop
novel
antimerscov
agent
evolv
epidem
attempt
provid
altern
solut
identifi
potenti
broadspectrum
antivir
agent
merscov
influenza
virus
small
compoundbas
forward
chemic
genet
approach
use
chemic
librari
consist
drug
compound
alreadi
market
reach
clinic
trial
unit
state
europ
asia
microsourc
discoveri
system
usa
assess
antimerscov
activ
identifi
drug
compound
cell
cultur
cytopath
effect
cpe
inhibit
viral
yield
reduct
plaqu
reduct
assay
pra
assay
well
drug
cytotox
clinic
isol
merscov
kindli
provid
r
fouchier
zaki
colleagu
isol
amplifi
one
addit
passag
vero
cell
make
work
stock
viru
tcid
ml
experiment
protocol
involv
live
merscov
isol
follow
standard
oper
procedur
approv
biosafeti
facil
previous
describ
influenza
viru
expand
chick
embryo
previous
describ
chemic
reagent
highthroughput
screen
ht
total
preexist
drug
compound
microsourc
discoveri
system
screen
influenza
viru
highthroughput
screen
ht
carri
fulli
autom
beckman
coulter
core
system
beckman
coulter
usa
integr
kendro
robot
co
incub
thermo
fisher
scientif
chemic
genet
unit
depart
microbiolog
research
center
infect
immunolog
li
kash
faculti
medicin
univers
hong
kong
previous
describ
modif
briefli
compound
ad
microtitr
plate
tpp
duplic
final
concentr
mm
mm
madinedarbi
canin
kidney
mdck
cell
per
well
ml
complet
eagl
minim
essenti
medium
emem
supplement
heatinactiv
fb
cell
inocul
moi
influenza
viru
detect
broadspectrum
antivir
infect
plate
incub
c
co
monitor
daili
use
leica
dm
invert
light
microscop
virusinduc
cpe
drug
gave
full
protect
mdck
cell
cpe
select
evalu
merscov
biosafeti
laboratori
cytotox
select
drug
ribavirin
mgml
introna
iuml
avonex
iuml
rebif
iuml
betaferon
iuml
mmf
mgml
determin
thiazolyl
blue
tetrazolium
bromid
mtt
assay
accord
manufactur
instruct
endpoint
effect
cytotox
concentr
tc
drug
compound
identifi
primari
hit
show
ec
less
equal
um
select
index
dilut
serum
free
mem
ad
confluent
vero
cell
cultur
plate
triplic
h
c
incub
drugcontain
media
remov
merscov
moi
ad
togeth
fresh
drugcompound
media
well
contain
approxim
cell
follow
h
adsorpt
c
viruscompound
mixtur
remov
cell
wash
time
mem
remov
unbound
viru
subsequ
media
antivir
compound
ad
cell
incub
h
c
co
humidifi
environ
cpe
examin
invert
light
microscopi
ml
supernat
collect
viru
quantif
previous
describ
modif
thereaft
ml
serum
free
mem
ml
mgml
mtt
solut
prepar
pb
filter
ad
well
monolay
incub
h
away
light
final
ml
sd
hcl
ad
incub
c
co
overnight
activ
read
od
refer
wavelength
od
interferon
noninterferon
drug
compound
lowest
effect
inhibitori
concentr
ec
highest
select
index
select
combin
studi
use
cpe
inhibit
assay
drug
compound
antivir
activ
mtt
assay
evalu
quantit
viru
yield
reduct
plaqu
reduct
assay
pra
perform
viru
yield
quantif
perform
quantit
rtpcr
use
total
nucleic
acid
extract
cultur
supernat
vero
cell
infect
merscov
day
postinfect
previous
describ
pra
perform
previous
describ
modif
briefli
perform
duplic
tissu
cultur
plate
tpp
vero
cell
seed
cellswel
mem
invitrogen
fb
day
carri
assay
h
incub
plaqueform
unit
pfu
merscov
viru
ad
cell
monolay
without
addit
drug
compound
plate
incub
h
c
co
atmospher
remov
unbound
viral
particl
aspir
media
wash
mem
monolay
overlaid
media
contain
low
melt
agaros
cambrex
mem
appropri
concentr
drug
compound
incub
h
next
well
fix
formaldehyd
bdh
overnight
remov
agaros
plug
monolay
stain
crystal
violet
bdh
plaqu
count
percentag
plaqu
inhibit
rel
control
without
addit
compound
plate
determin
drug
compound
concentr
ec
cellular
cytotox
concentr
cc
calcul
use
sigma
plot
spss
excel
addin
pra
carri
triplic
repeat
twice
confirm
highthroughput
screen
ht
ten
drug
compound
name
mycophenol
acid
flufenam
acid
tolfenam
acid
meclofenam
sodium
mefenam
acid
ribavirin
mercaptopurin
pyrimethamin
emetin
estradiol
identifi
primari
hit
protect
result
chemic
librari
screen
influenza
viru
tabl
neuraminidas
inhibitor
identifi
includ
chemic
librari
amantadin
identifi
viru
strain
gene
mutat
confer
drug
resist
use
ec
tc
hit
select
criteria
mycophenol
acid
exhibit
low
ec
mm
high
select
index
mercaptopurin
competit
select
revers
inhibitor
sarscov
papainlik
proteas
addit
mycophenol
acid
sigmaealdrich
usa
ribavirin
tianxin
pharmaceut
china
intron
recombin
scheringplough
usa
avonex
recombin
biogen
idec
denmark
rebif
recombin
merck
serono
itali
betaferon
recombin
bayer
schere
pharma
germani
imukin
recombin
boehring
ingelheim
germani
nelfinavir
mesyl
hydrat
agouron
pharmaceut
usa
lopinavir
abbott
usa
also
test
mtt
assay
document
vitro
antisarscov
activ
previou
report
among
mycophenol
acid
ribavirin
intron
avonex
rebif
betaferon
show
antimerscov
activ
test
concentr
tabl
cpe
complet
absent
vero
cell
infect
merscov
day
postinfect
concentr
mgml
mycophenol
acid
mgml
ribavirin
decreas
absent
test
concentr
intron
avonex
rebif
betaferon
tabl
combin
studi
show
ec
mycophenol
acid
lower
time
presenc
iuml
betaferon
ec
betaferon
lower
time
presenc
mgml
mycophenol
acid
tabl
mean
baselin
viral
load
cell
cultur
supernat
without
drug
ae
log
copiesml
reduct
viral
load
compar
baselin
cell
cultur
supernat
inocul
six
drug
fig
reduct
viral
load
cell
cultur
supernat
inocul
mycophenol
acid
ribavirin
rebif
betaferon
reduct
viral
load
cell
cultur
supernat
iuml
betaferon
reduct
highest
concentr
iuml
fig
largest
reduct
viral
load
clinic
relev
drug
level
nearli
reduct
mgml
mycophenol
acid
mycophenol
acid
ribavirin
rebif
achiev
plaqu
reduct
concentr
mgml
mgml
iuml
respect
fig
maximum
percentag
plaqu
reduct
achiev
intron
avonex
betaferon
iuml
iuml
iuml
respect
fig
pra
betaferon
achiev
plaqu
reduct
iuml
fig
novel
antivir
target
sar
coronaviru
influenza
viru
identifi
previous
use
small
compoundbas
forward
chemic
genet
approach
similar
studi
identifi
ten
compound
among
approv
drug
primari
hit
chemic
librari
screen
possess
antivir
activ
may
offer
potenti
therapi
evolv
merscov
epidem
influenza
viru
instead
merscov
use
initi
screen
manipul
requir
biosafetli
level
iii
laboratori
human
betacoronavirus
use
slow
replic
low
viral
titr
cell
cultur
among
identifi
drug
compound
mycophenol
acid
exhibit
ec
mm
common
cutoff
valu
lead
compound
detect
high
select
index
addit
test
agent
report
vitro
activ
sarscov
andor
merscov
imukin
hiv
proteas
inhibitor
nelfinavir
mesyl
hydrat
lopinavir
show
suboptim
ec
initi
cpe
inhibit
assay
therefor
evalu
togeth
mycophenol
acid
four
drug
compound
five
prepar
name
ribavirin
intron
avonex
rebif
betaferon
show
vitro
antimerscov
activ
vari
magnitud
across
four
assay
mycophenol
acid
select
noncompetit
revers
inhibitor
monophosph
dehydrogenas
impdh
inhibit
prolifer
b
lymphocyt
product
immunoglobulin
deplet
lymphocyt
guansin
deoxyguanosin
nucleotid
pool
major
clinic
indic
prevent
graft
reject
solid
organ
haematopoeit
stem
cell
transplant
addit
potent
immunosuppress
activ
mycophenol
acid
also
broad
activ
vitro
andor
anim
model
differ
virus
includ
west
nile
japanes
enceph
yellow
fever
dengu
chikungunya
possibl
hepat
b
virus
furthermor
inhibit
vitro
vivo
replic
hepat
c
viru
augment
interferonstimul
gene
express
deplet
guanosin
combin
treatment
interferona
show
addit
effect
interferonstimul
gene
express
enhanc
interferoninduc
luciferas
report
activ
coronavirus
mycophenol
acid
test
test
test
remark
neg
defin
involv
defin
involv
defin
e
involv
defin
involv
druginduc
toxic
effect
vero
cell
found
ineffect
sarscov
anim
model
although
significantli
increas
viral
load
lung
sarsinfect
balbc
mice
ribavirin
unawar
data
activ
human
coronavirus
studi
first
demonstr
anticoronaviru
activ
mycophenol
acid
novel
merscov
addit
mycophenol
acid
vitro
find
indic
ribavirin
interferona
interferonb
antimerscov
activ
vitro
case
sarscov
antivir
activ
vitro
suscept
test
conflict
none
test
system
largescal
random
control
trial
result
clinic
trial
involv
use
sar
often
confound
concomit
use
corticosteroid
although
clinic
use
merscov
infect
describ
recent
studi
found
ribavirin
vitro
antimerscov
activ
high
concentr
potenti
given
togeth
anoth
studi
show
merscov
time
sensit
pegyl
interferona
sarscov
vero
cell
possibl
relat
lineagespecif
genet
differ
two
coronavirus
merscov
lack
homolog
sarscov
protein
respons
blockad
interferoninduc
nuclear
transloc
phosphoryl
transcript
factor
furthermor
delay
aberr
induct
inflammatori
cytokin
chemokin
merscov
might
support
use
adjunct
immunomodulatori
treatment
combin
antivir
patient
mer
among
four
prepar
interferon
test
betaferon
exhibit
lowest
ec
iuml
mean
peak
serum
concentr
iuml
subcutan
dose
million
iu
intraven
dose
million
million
iu
although
prepar
interferon
also
demonstr
vitro
antimerscov
activ
ec
gener
peak
serum
concentr
achiev
usual
therapeut
dose
combin
treatment
consist
mycophenol
acid
betaferon
result
reduct
ec
mycophenol
acid
vero
cell
iuml
betaferon
reduct
ec
betaferon
vero
cell
mgml
mycophenol
acid
find
may
provid
basi
combin
mycophenol
acid
betaferon
futur
clinic
trial
compar
ribavirin
interferon
mycophenol
acid
exhibit
number
attribut
support
practic
use
merscov
infect
commonli
avail
two
form
prodrug
mycophenol
mofetil
salt
mycophenol
sodium
could
given
oral
parenter
serum
concentr
mycophenol
acid
peak
around
mgml
mg
oral
dose
mycophenol
mofetil
mgml
mg
oral
dose
mycophenol
sodium
far
exce
ec
mgml
time
higher
concentr
replic
merscov
inhibit
cell
cultur
pra
averag
plasma
elimin
halfliv
h
h
mg
oral
dose
mg
intraven
dose
mycophenol
mofetil
respect
usual
regimen
consist
mg
twice
daili
oral
mg
twice
daili
intraven
mycophenol
mofetil
would
suffici
achiev
level
well
ec
throughout
dose
interv
contrast
ec
ribavirin
merscov
mgml
margin
effect
cell
line
greatli
exce
drug
serum
concentr
usual
oral
dose
peak
concentr
high
intraven
dose
may
reach
approxim
mgml
human
steadyst
requir
least
week
achiev
furthermor
use
ribavirin
henc
also
combin
may
limit
clinic
set
signific
proport
patient
merscov
infect
develop
acut
renal
failur
often
requir
renal
replac
therapi
suggest
system
ribavirin
best
avoid
patient
creatinin
clearanc
mlmin
increas
risk
haemolyt
anaemia
although
mycophenol
acid
may
also
associ
acut
renal
impair
dosag
adjust
set
gener
well
establish
potent
vitro
antimerscov
activ
mycophenol
acid
may
allow
use
monotherapi
concomit
interferon
avail
toler
patient
final
drug
level
monitor
mycophenol
mofetil
gener
avail
tertiari
hospit
usual
referr
center
case
sever
merscov
infect
requir
intens
care
facil
extracorpor
membran
oxygen
howev
risk
immunosuppress
onset
adapt
immun
respons
polar
toward
deleteri
respons
mycophenol
acid
need
consid
one
possibl
approach
short
cours
mycophenol
mofetil
combin
interferon
particularli
provid
synergist
antivir
immuneenhanc
effect
merscov
option
consid
studi
random
control
clinic
trial
highli
fatal
diseas
number
limit
studi
firstli
cytotox
assay
like
underestim
subtl
effect
candid
compound
host
cell
growth
metabol
exampl
ribavirin
inhibit
replic
uninfect
mdck
cell
concentr
mgml
caus
overt
cytotox
much
higher
concentr
reach
secondli
use
vero
cell
alon
studi
antivir
activ
ribavirin
vero
cell
describ
compar
resist
ribavirin
due
ineffici
convers
drug
monoand
triphosph
form
howev
decid
perform
experi
use
anoth
cell
line
done
anoth
recent
report
use
vero
cell
line
also
demonstr
antimerscov
activ
high
ribavirin
concentr
similar
find
would
import
extend
vitro
studi
human
respiratori
epitheli
cell
system
explant
optim
treatment
option
merscov
infect
studi
antimerscov
activ
potenti
anticoronaviru
agent
previous
identifi
sarscov
undertaken
replic
mani
coronavirus
includ
sarscov
merscov
requir
proteolyt
process
replicas
polyprotein
two
viral
cystein
proteas
chymotrypsinlik
proteas
papainlik
proteas
plpro
howev
proteas
inhibitor
nelfinavir
lopinavir
found
activ
vitro
studi
helicas
inhibitor
anoth
group
agent
vitro
antisarscov
activ
antimerscov
activ
remain
undetermin
inhal
nitric
oxid
use
rescu
therapi
sar
might
use
treat
merscov
infect
organ
nitric
oxid
donor
snitronacetylpenicillamin
also
show
antimerscov
activ
antivir
peptid
neutral
antibodi
design
heptad
repeat
region
may
inhibit
membran
fusion
cell
entri
sarscov
could
theoret
har
merscov
sinc
region
share
signific
homolog
amongst
betacoronavirus
agent
vitro
antisarscov
activ
glycyrrhizin
baicalin
reserpin
aescin
valinomycin
niclosamid
aurintricarboxyl
acid
mizoribin
indomethacin
chloroquin
experiment
agent
like
small
interf
rna
sirna
inhibitor
target
bind
interfac
domian
receptor
vivo
also
evalu
test
agent
studi
problem
either
commerci
avail
therapeut
level
easili
achiev
clinic
recent
cyclophilin
inhibitor
cyclosporin
avail
commerci
also
report
exhibit
antimerscov
anticoronaviru
activ
cell
cultur
viral
load
studi
evalu
potenti
therapeut
effect
commerci
avail
agent
vitro
activ
conduct
random
clinic
trial
good
anim
model
mer
wide
avail
stage
